EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Molecular Basis of Synergistic Causal Effect of Dual GLP-1R and GIPR Agonists for Risk Reduction in Diabetic Retinopathy, Alzheimer Disease, and Coronary Artery Disease in Diabetic Patients

Jiehui Xu, Yibeltal A Ashebir, Yongzhao Shao iD

Genes · 2026

DOI: 10.3390/genes17060602 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genes, 2026. Verfasst von Jiehui Xu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Population Health, NYU Grossman School of Medicine, New York, NY 10016, USA. Hauptthemen laut MEDLINE: Coronary Artery Disease, Alzheimer Disease, Glucagon-Like Peptide-1 Receptor Agonists, Diabetic Retinopathy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CDC HHS, NIA NIH HHS, Centers for Disease Control and Prevention.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The dual agonism of glucagon-like peptide-1 receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR) becomes a groundbreaking treatment for type 2 diabetes (T2D) that achieves robust glycemic control and maintains body weight. It also induces potential risk reduction in diabetic retinopathy (DR), Alzheimer disease (AD), and heart diseases including coronary artery disease (CAD) in treated T2D patients. To date, the molecular basis underpinning the remarkable causal treatment effects and synergy of the dual agonism of GLP-1R and GIPR on risk reduction in T2D, CAD, DR and AD has not been systematically investigated.

Methods

To elucidate the treatment effects and potential synergy of dual GLP-1R/GIPR agonism on risk reduction in T2D, CAD, DR and AD while minimizing the impact of confounders, we used a robust cis-Mendelian randomization (cis-MR) with a principal component-based generalized method of moments (PC-GMM) where blood-based glycated hemoglobin (HbA1c), high- and low-density lipoprotein cholesterol (HDL-c, LDL-c), and BMI were used as mediating biomarkers.

Results

Our cis-MR analyses confirmed a synergistic causal protective effect of dual GLP-1R/GIPR agonism on T2D via HbA1c reduction [OR = 0.17; 95% CI = (0.11, 0.26); p = 3.68 × 10−17] which is more significant than either GLP-1R agonism or GIPR agonism alone. Similarly, the causal protective effect of dual GLP-1R/GIPR agonism via HbA1c reduction was also significant for DR [OR = 0.20; 95% CI = (0.11, 0.36); p = 9.22 × 10−8]. Further, our multivariate cis-MR (or cis-MVMR) analyses revealed that after adjusting for HbA1c, a synergistic protective effect on DR via a reduction in LDL-c is significant in dual GLP-1R/GIPR agonism [OR = 0.57; 95% CI = (0.29, 0.94)], while the protective effect on DR of LDL-c reduction is non-significant in either GLP-1R agonism or GIPR agonism alone. Also, after adjusting for HbA1c, the multivariate cis-MR results showed significant protective effects on AD via a reduction in LDL-c in GLP-1R/GIPR agonism [OR = 0.44; 95% CI = (0.25, 0.81)]. Importantly, the multivariate cis-MR results also revealed that dual GLP-1R/GIPR agonism has significant protective effects on CAD via both a reduction in BMI [OR = 0.46; 95% CI = (0.28, 0.75)] and an improvement in HDL [OR = 0.59; 95% CI = (0.39, 0.90)]. This is in support of the hypothesis that dual GLP-1R/GIPR agonism has a synergistic protective effect on CAD that is stronger than that of GLP-1R agonism alone, which yielded a non-significant causal effect for both HDL and BMI, and GIPR agonism alone also yielded a non-significant causal effect for HDL when adjusted for BMI.

Conclusions

These novel findings have significant implications for repurposing dual incretin agonism in terms of diabetic drugs to serve as a unifying, precision prevention strategy against CAD, DR and AD as leading drivers of mortality and morbidity in diabetic patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Coronary Artery DiseaseAlzheimer DiseaseGlucagon-Like Peptide-1 Receptor AgonistsDiabetic RetinopathyDiabetes Mellitus, Type 2Receptors, Gastrointestinal HormoneHumansGlucagon-Like Peptide-1 ReceptorGlycated HemoglobinMaleHypoglycemic AgentsFemale

Stichwörter der Autor:innen

Alzheimer’s diseasesPC-GMMantidiabetic drugcis-MRcoronary artery diseasediabetic retinopathymultivariate Mendelian Randomizationsynergistic causal effect

Substanzen

Glucagon-Like Peptide-1 Receptor Agonistsgastric inhibitory polypeptide receptorReceptors, Gastrointestinal HormoneGlucagon-Like Peptide-1 ReceptorGLP1R protein, humanGlycated HemoglobinHypoglycemic Agents

Autor:innen und Institutionen

  • Department of Population Health, NYU Grossman School of Medicine, New York, NY 10016, USA.

ORCID-Profile: Yongzhao Shao

Förderung

  • CDC HHS
  • NIA NIH HHS
  • Centers for Disease Control and Prevention
  • National Institute on Aging

Zitieren

APA

Xu, J., Ashebir, Y. A., & Shao, Y. (2026). Molecular Basis of Synergistic Causal Effect of Dual GLP-1R and GIPR Agonists for Risk Reduction in Diabetic Retinopathy, Alzheimer Disease, and Coronary Artery Disease in Diabetic Patients. Genes. https://doi.org/10.3390/genes17060602

Vancouver

Xu J, Ashebir YA, Shao Y. Molecular Basis of Synergistic Causal Effect of Dual GLP-1R and GIPR Agonists for Risk Reduction in Diabetic Retinopathy, Alzheimer Disease, and Coronary Artery Disease in Diabetic Patients. Genes. 2026. doi:10.3390/genes17060602

BibTeX
@article{Xu2026,
  author = {Xu, Jiehui and Ashebir, Yibeltal A and Shao, Yongzhao},
  title = {Molecular Basis of Synergistic Causal Effect of Dual GLP-1R and GIPR Agonists for Risk Reduction in Diabetic Retinopathy, Alzheimer Disease, and Coronary Artery Disease in Diabetic Patients},
  journal = {Genes},
  year = {2026},
  doi = {10.3390/genes17060602}
}
Kostenlos starten →